Use of SGLT2 Inhibitors in Patients With HF With and Without Type 2 Diabetes An Endocrinologist's Perspective

被引：0
|
作者：
Butler, Javed [1 ,2 ,3 ]
Pessah-Pollack, Rachel [4 ]
机构：
[1] Baylor Scott & White Res Inst, 3434 Live Oak St,Suite 501, Dallas, TX 75204 USA
[2] Baylor Scott & White Hlth, Dallas, TX USA
[3] Univ Mississippi, Sch Med, Jackson, MS USA
[4] NYU, Sch Med, New York, NY USA
来源：
JACC-HEART FAILURE | 2024年 / 12卷 / 06期
关键词：
heart failure; SGLT2; inhibitors; type; 2; diabetes;
D O I：
10.1016/j.jchf.2024.01.024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：S4 / S6
页数：3
相关论文
共 50 条
  • [41] SGLT2 inhibitors and autophagy in diabetes
    Yaribeygi, Habib
    Maleki, Mina
    Atkin, Stephen L.
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    CELL BIOCHEMISTRY AND FUNCTION, 2023, 41 (04) : 392 - 398
  • [42] Ketoacidosis in Type 2 Diabetes with and without SGLT2 Inhibitor Therapy
    Koerbel, Theresa
    Zitterl, A.
    Jagoutz, T.
    Peric, S.
    Stulnig, T. M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S765 - S765
  • [43] In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia
    Rachmasari, Kharisa
    Montori, Victor M.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (09) : JC104 - JC104
  • [44] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Evans, Marc
    Hicks, Debbie
    Patel, Dipesh
    Patel, Vinod
    McEwan, Phil
    Dashora, Umesh
    DIABETES THERAPY, 2020, 11 (01) : 37 - 52
  • [45] SGLT2 inhibitors and renal complications in type 1 diabetes
    Petrie, John R.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (10): : 803 - 805
  • [46] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Marc Evans
    Debbie Hicks
    Dipesh Patel
    Vinod Patel
    Phil McEwan
    Umesh Dashora
    Diabetes Therapy, 2020, 11 : 37 - 52
  • [47] Type 2 Diabetes: SGLT2 Inhibitors and DPP4 Inhibitors in Comparison
    Simon, Annika
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (16) : 1002 - 1002
  • [48] SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
    Patel, Tejas
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (03) : JC27 - JC27
  • [49] Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients
    Danpanichkul, Pojsakorn
    Manosroi, Worapaka
    Nilsirisuk, Tharadon
    Tosukhowong, Theetouch
    FRONTIERS IN ENDOCRINOLOGY, 2024, 14
  • [50] Intensification of Human Insulin Therapy with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Dzida, Grzegorz J.
    Gajda, Piotr
    Masierek, Malgorzata
    DIABETES, 2024, 73
12345